scholarly journals Review: The Tumor-Like Phenotype of Rheumatoid Synovium: Molecular Profiling and Prospects for Precision Medicine

2018 ◽  
Vol 70 (5) ◽  
pp. 637-652 ◽  
Author(s):  
Sungyong You ◽  
Jung Hee Koh ◽  
Lin Leng ◽  
Wan-Uk Kim ◽  
Richard Bucala
2018 ◽  
Vol 24 (2) ◽  
pp. 93-103 ◽  
Author(s):  
Camila D.M. Campos ◽  
Joshua M. Jackson ◽  
Małgorzata A. Witek ◽  
Steven A. Soper

2017 ◽  
Vol 471 (2) ◽  
pp. 243-255 ◽  
Author(s):  
Tariq Al-Zaid ◽  
Wei-Lien Wang ◽  
Neeta Somaiah ◽  
Alexander J. Lazar

2019 ◽  
Vol 12 (1) ◽  
Author(s):  
Apostolia-Maria Tsimberidou ◽  
David S. Hong ◽  
Jennifer J. Wheler ◽  
Gerald S. Falchook ◽  
Filip Janku ◽  
...  

Abstract Background In 2007, we initiated IMPACT, a precision medicine program for patients referred for participation in early-phase clinical trials. We assessed the correlation of factors, including genomically matched therapy, with overall survival (OS). Patients and methods We performed molecular profiling (Clinical Laboratory Improvement Amendments) (genes ≤ 182) for patients with lethal/refractory advanced cancers referred to the Phase 1 Clinical Trials Program. Matched therapy, if available, was selected on the basis of genomics. Clinical trials varied over time and included investigational drugs against various targets (single agents or combinations). Patients were followed up for up to 10 years. Results Of 3487 patients who underwent tumor molecular profiling, 1307 (37.5%) had ≥ 1 alteration and received therapy (matched, 711; unmatched, 596; median age, 57 years; 39% men). Most common tumors were gastrointestinal, gynecologic, breast, melanoma, and lung. Objective response rates were: matched 16.4%, unmatched 5.4% (p < .0001); objective response plus stable disease ≥ 6 months rates were: matched 35.3% and unmatched 20.3%, (p < .001). Respective median progression-free survival: 4.0 and 2.8 months (p < .0001); OS, 9.3 and 7.3 months; 3-year, 15% versus 7%; 10-year, 6% vs. 1% (p < .0001). Independent factors associated with shorter OS (multivariate analysis) were performance status > 1 (p < .001), liver metastases (p < .001), lactate dehydrogenase levels > upper limit of normal (p < .001), PI3K/AKT/mTOR pathway alterations (p < .001), and non-matched therapy (p < .001). The five independent factors predicting shorter OS were used to design a prognostic score. Conclusions Matched targeted therapy was an independent factor predicting longer OS. A score to predict an individual patient’s risk of death is proposed. Trial registration ClinicalTrials.gov, NCT00851032, date of registration February 25, 2009.


Oncotarget ◽  
2015 ◽  
Vol 6 (38) ◽  
pp. 40642-40654 ◽  
Author(s):  
Vivek Subbiah ◽  
Michael J. Wagner ◽  
Mary F. McGuire ◽  
Nawid M. Sarwari ◽  
Eswaran Devarajan ◽  
...  

2021 ◽  
Vol 11 (10) ◽  
pp. 1019
Author(s):  
Vianney Gilard ◽  
Stéphane Derrey ◽  
Stéphane Marret ◽  
Soumeya Bekri ◽  
Abdellah Tebani

Since the inception of their profession, neurosurgeons have defined themselves as physicians with a surgical practice. Throughout time, neurosurgery has always taken advantage of technological advances to provide better and safer care for patients. In the ongoing precision medicine surge that drives patient-centric healthcare, neurosurgery strives to effectively embrace the era of data-driven medicine. Neuro-oncology best illustrates this convergence between surgery and precision medicine with the advent of molecular profiling, imaging and data analytics. This convenient convergence paves the way for new preventive, diagnostic, prognostic and targeted therapeutic perspectives. The prominent advances in healthcare and big data forcefully challenge the medical community to deeply rethink current and future medical practice. This work provides a historical perspective on neurosurgery. It also discusses the impact of the conceptual shift of precision medicine on neurosurgery through the lens of neuro-oncology.


2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 2539-2539 ◽  
Author(s):  
Alice P. Chen ◽  
Mickey Williams ◽  
Shivaani Kummar ◽  
Chih-Jian Lih ◽  
Vivekananda Datta ◽  
...  

2019 ◽  
Vol 25 (5) ◽  
pp. 711-712 ◽  
Author(s):  
Christophe Le Tourneau ◽  
Edith Borcoman ◽  
Maud Kamal

2015 ◽  
Vol 108 (4) ◽  
pp. djv362 ◽  
Author(s):  
Christophe Le Tourneau ◽  
Maud Kamal ◽  
Apostolia-Maria Tsimberidou ◽  
Philippe Bedard ◽  
Gaëlle Pierron ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document